Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 1 20Phase 1/2 6Phase 3 1Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 259Lymphoid 13Tumor-Agnostic 5Gynecologic 3Thoracic 1Sarcoma 1Other solid neoplasm 1NET 1Genitourinary 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 282Cisplatin 225Pemetrexed 196Paclitaxel 151Docetaxel 132pembrolizumab 109Gemcitabine 94Etoposide 63Erlotinib Hydrochloride 59Radiotherapy 54Vinorelbine 47durvalumab 46Gefitinib 46Bevacizumab 46atezolizumab 41Nivolumab 40Drug Therapy 34osimertinib 30Topotecan 29tislelizumab 23130-nm albumin-bound paclitaxel 23Radiosurgery 21Ipilimumab 18Crizotinib 18Magnetic Resonance Spectroscopy 15Albumin-Bound Paclitaxel 15Surgical Procedures, Operative 14aumolertinib 13Platinum 13Injections 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Oxaliplatin × Thoracic × Clear all
NCT00087802 2009-04-16

Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)

Sanofi

Phase 3 Completed
383 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡